RSU vesting grants Natera (NASDAQ: NTRA) president 44,698 shares of stock

Rhea-AI Filing Summary

Natera, Inc. executive Solomon Moshkevich reported an equity award tied to performance goals. On January 14, 2026, 44,698 shares of Natera common stock were acquired at $0 per share when a performance threshold under a previously granted performance-based restricted stock unit (RSU) award was certified.

The RSU grant, originally awarded on January 27, 2023, vests in tranches upon achieving milestones based on time and business performance criteria. Following this vesting event, Moshkevich directly beneficially owns 168,197 shares of Natera common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Moshkevich Solomon

Role PRESIDENT, CLINICALDIAGNOSTICS

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	44,698	$0.00	--

Holdings After Transaction: Common Stock — 168,197 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moshkevich Solomon

(Last) (First) (Middle)

C/O NATERA, INC.

13011 MCCALLEN PASS BUILDING A SUITE 100

(Street)

AUSTIN TX 78753

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Natera, Inc. [ NTRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT, CLINICALDIAGNOSTICS

3. Date of Earliest Transaction (Month/Day/Year)
01/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/14/2026		A		44,698(1)	A	$0	168,197	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On January 27, 2023, the Reporting Person was granted a performance-based Restricted Stock Unit (RSU) award which vests in tranches upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria. On January 14, 2026, the performance threshold with respect to one milestone under the RSUs was certified, resulting in the vesting of 44,698 shares of Common Stock.

	/s/ Tami Chen, Attorney-in-Fact	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Natera (NTRA) report in this Form 4?

The filing reports that executive Solomon Moshkevich, President, Clinical Diagnostics, acquired 44,698 shares of Natera common stock at $0 per share through RSU vesting on January 14, 2026.

Was the Natera (NTRA) insider transaction a purchase or an equity award?

The transaction was an equity award vesting, not an open-market purchase. Performance-based restricted stock units (RSUs) vested, resulting in delivery of 44,698 common shares when a performance milestone was certified.

What is the origin of the RSUs that vested for the Natera (NTRA) executive?

The RSUs come from a performance-based award granted on January 27, 2023, which vests in tranches upon meeting milestones tied to the passage of time and certain business performance criteria.

How many Natera (NTRA) shares does the insider own after this Form 4 transaction?

After the vesting of 44,698 shares, the reporting person beneficially owns 168,197 shares of Natera common stock, held with direct ownership.

What triggered the vesting of RSUs in this Natera (NTRA) insider filing?

On January 14, 2026, a performance threshold for one milestone under the performance-based RSU award was certified, causing 44,698 shares of common stock to vest.

What role does the reporting person hold at Natera (NTRA)?

The reporting person, Solomon Moshkevich, serves as President, Clinical Diagnostics at Natera, Inc., as indicated in the Form 4.